Intrinsic Alpha

Company Snapshot

Viridian Therapeutics, Inc. investment report

Start with VRDN at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.

Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$31.44 -0.88%

-$0.15 today

Market cap
$3.57B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 4.02M

Average 2.86M

Intrinsic Value

VRDN Intrinsic Value

Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.

Viridian Therapeutics, Inc.

NASDAQ:VRDN

Intrinsic Alpha fair value

Locked

Current Price

$31.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Monitor VRDN

Get notified when the price moves into your range

Use alerts to turn the valuation into an action plan instead of checking the stock manually.

Price alerts

Get notified when VRDN drops below your target

Current price baseline

$31.44

Current price

Current price $31.44

Selected target$25.15

Sign in to activate price alerts.

Price History

How has VRDN traded over time?

Review how the market has priced Viridian Therapeutics, Inc. over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.

Price history

Dividend-adjusted closing price

Period change

+9.62%

Period high

$33.78

Period low

$13.30

Latest

$31.44

Investment Notes

Capture the investment case

Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.

My notes

Journal entries for VRDN

Sign in to keep notes

Keep your research and decisions in your personal journal.

Sign in / Sign up

Fundamental Analysis

Test company quality against your thesis

Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.

Earnings Quality

Follow revenue through to net income

Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.

VRDN Earnings Waterfall · TTM

NASDAQ:VRDN · Revenue to Net Income

Key Ratios

EPS$-3.53
Gross Margin39.4%
Net Margin-52596.3%
P/E Ratio-8.0
P/S Ratio10293.9

Analysis

$71.1M of revenue converted into -$387.0M of net income for the selected period. Gross margin is 39.4% and net margin is -52596.3%, showing how much revenue survives after costs and taxes. EPS is $-3.53, tying the income statement back to per-share earnings.

Revenue Mix

See which products and regions drive the business

Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.

Revenue by segment

Where VRDN earns its revenue, as reported in company filings

  • License
  • Collaboration
  • Collaboration Revenue
  • Reimbursement Revenue
  • Grant
  • Milestone Payments
Revenue by segment for FY2025
Segment · FY2025 Revenue Share YoY
License$70M98.8%—
Collaboration$849K1.2%—

Figures in USD.

Financial Position

Check what supports the company underneath the income statement

The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$165.0M
Short-term Investments$816.5M
Receivables$75.0M
Other Current$24.7M
Total Current Assets$1.1B
PP&E (Net)$4.8M
Intangible Assets$10.0M
Other Non-current$1.1M
Total Non-current Assets$16.0M
Total Assets$1.1B

Analysis

Selected assets total $1.1B for Latest. The largest visible component is Short-term Investments at $816.5M, about 74.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Cash Generation

Test whether profit turns into cash

Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$342.6M
+ D&A$460.0K
+ Stock-Based Comp$44.3M
+ Deferred Tax$0
+ Working Capital$23.0M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$276.4M
- Capex-$495.0K
= Free Cash Flow-$276.9M

Analysis

FY2025 free cash flow is -$276.9M. FCF conversion is 80.8% of net income. Operating cash flow was -$276.4M, with capex of -$495.0K. The largest bridge item is Stock-Based Comp at $44.3M.

Quality Snapshot

Check the numbers that compound value

Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/A+241.9%+23359.9%
Equity
N/AN/A-11.6%-13.9%
Cash
N/AN/A+10.9%+113.2%
ROIC
N/A-43.4%-47.2%-43.8%

Analysis

Latest growth is strongest in Revenue at +23359.9% and weakest in ROIC at -43.8%. Three-year average ROIC is -47.2%, which helps show whether that growth is being earned efficiently.

Growth Profile

Compare historical growth with forward expectations

Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+241.9%
+78.8% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +241.9% over three years. Forward estimates point to Revenue at +78.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Management

Judge how Viridian Therapeutics, Inc. allocates capital

Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.

Capital Efficiency

Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-47.4%

avg 279.3%

ROIC

-43.8%

avg -266.7%

ROA

-38.1%

avg -81.8%

Analysis

ROA is currently the strongest return metric at -38.1% versus its period average of -81.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Dividend Record

A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.

Dividends

Dividend history, growth & yield

Dividends

Yield

0.00%

Annual Div/Share

$0.00

Payout Ratio

0.0%

Frequency

—

Shareholder Yield

0.00%

Next Ex-Date

Not announced

Next Payment

—

Analysis

The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.

Owner Returns

Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.

Shareholder Returns

Dividend, buyback & debt paydown yields

Management

Dividend Yield (TTM)

0.00%

Buyback Yield (TTM)

0.00%

Debt Paydown (TTM)

0.00%

Total Yield (TTM)

0.00%

Showing limited history. Sign in for more

Analysis

Total TTM shareholder yield is 0.00% including 0.00% from debt paydown. The largest current contributor is dividends at 0.00%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.

Insider Activity

Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.

Insider Trading

SEC Form 4 transactions — last 12 months

Management

Buys

1

$20.00M

Sells

2

$315,795.52

Net Transaction Value

+$19.68M

Net buying

Most Active

Tousignant Jennifer

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 19, 26

Tousignant Jennifer

Direct

Sell$245K
May 11, 26

Fairmount Funds Management LLC

Indirect

Buy$20M
Dec 31, 25

Tousignant Jennifer

Direct

Sell$70.8K

Summary

Insiders reported 1 buys worth $20.00M and 2 sells worth $315,795.52 over the last 12 months. That adds up to net buying of $19.68M. Tousignant Jennifer was the most active insider with 2 transactions.

Leadership

Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.

Management

Key executives, compensation & ownership

View management
NameTitleCompensationAgeShares OwnedOwnership %

Stephen F. Mahoney

Chief Executive Officer, President & DirectorUSD 1.34M5533.35K0.04%

Thomas W. Beetham

Chief Operating OfficerUSD 972.98K5613.36K0.01%

Radhika Tripuraneni

Chief Medical OfficerUSD 840.69K460<0.01%

Jennifer Tousignant

Chief Legal Officer & Corporate SecretaryUSD 819.95K530<0.01%

Seth Harmon

Chief Financial OfficerUSD 785.65K457.85K<0.01%

Melissa Manno

Chief Human Resources Officer————

Eric N. Olson

Co-Founder & Chairman of Scientific Advisory Board————

Marvin H. Caruthers

Co-Founder & Scientific Advisory Board Member—86——

Michael R. Bristow

Co-Founder & Member of the Scientific Advisory Board—81——

Vahe Bedian

Co-Founder & Scientific Advisor————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 19, 2026.

Alternatives to VRDN

Compare Viridian Therapeutics, Inc. with similar companies

A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.

Analysts

What Wall Street expects from VRDN

Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.

Analyst Targets

See where analysts expect VRDN to trade next

Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for VRDN.

Sign in free

Analyst Ratings

How analysts rate VRDN today

See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for VRDN.

Sign in free

Company Overview

Understand how Viridian Therapeutics, Inc. makes money

Ground the financial evidence in the company profile, business description, and key facts.

Key Information

Filings
NameViridian Therapeutics, Inc.
TickerVRDN
ExchangeNASDAQ Capital Market
IPO DateJun 18, 2014
IndustryBiotechnology
SectorHealthcare
Market Cap$3.57B
Shares Out90.00M
LocationWaltham, MA, US

Stock Analysis

Turn the VRDN report into your next decision

Record your conclusion, evidence, and concerns in a structured analysis workspace.

Investment analysis

Turn VRDN research into a decision

Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.

NASDAQ:VRDN
Know the Business
Test the Moat
Management
Intrinsic Value

Sign in on the next page to save a private analysis.

Start analysis

FAQ

Common questions about VRDN

Resolve the remaining questions before moving into the detailed workspaces.

Explore

Continue your research

Open the detailed valuation, financial, health, and management workspaces.